CN105315363A - 一种普瑞巴林人工抗原的制备方法 - Google Patents
一种普瑞巴林人工抗原的制备方法 Download PDFInfo
- Publication number
- CN105315363A CN105315363A CN201510785142.8A CN201510785142A CN105315363A CN 105315363 A CN105315363 A CN 105315363A CN 201510785142 A CN201510785142 A CN 201510785142A CN 105315363 A CN105315363 A CN 105315363A
- Authority
- CN
- China
- Prior art keywords
- lyrica
- artificial antigen
- pregabalin
- liquid
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 73
- 239000000427 antigen Substances 0.000 title claims abstract description 50
- 102000036639 antigens Human genes 0.000 title claims abstract description 50
- 108091007433 antigens Proteins 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 229960001233 pregabalin Drugs 0.000 title abstract description 12
- 229940098773 bovine serum albumin Drugs 0.000 claims abstract description 24
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims abstract description 19
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940009697 lyrica Drugs 0.000 claims description 60
- 239000007788 liquid Substances 0.000 claims description 22
- 238000006243 chemical reaction Methods 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 12
- 239000011259 mixed solution Substances 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000013016 damping Methods 0.000 claims description 9
- 239000012530 fluid Substances 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims description 4
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 4
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 claims description 3
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 3
- 238000013019 agitation Methods 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 229910000071 diazene Inorganic materials 0.000 claims description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 229910001415 sodium ion Inorganic materials 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 10
- 238000000034 method Methods 0.000 abstract description 10
- 238000003018 immunoassay Methods 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 4
- 238000005917 acylation reaction Methods 0.000 abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 150000002148 esters Chemical class 0.000 abstract description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000003053 immunization Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 230000031700 light absorption Effects 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 206010012218 Delirium Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 238000004817 gas chromatography Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000010408 sweeping Methods 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000599 controlled substance Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004424 eye movement Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510785142.8A CN105315363B (zh) | 2015-11-16 | 2015-11-16 | 一种普瑞巴林人工抗原的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510785142.8A CN105315363B (zh) | 2015-11-16 | 2015-11-16 | 一种普瑞巴林人工抗原的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105315363A true CN105315363A (zh) | 2016-02-10 |
CN105315363B CN105315363B (zh) | 2018-11-30 |
Family
ID=55243751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510785142.8A Active CN105315363B (zh) | 2015-11-16 | 2015-11-16 | 一种普瑞巴林人工抗原的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105315363B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113087638A (zh) * | 2021-03-11 | 2021-07-09 | 杭州同舟生物技术有限公司 | 一种普瑞巴林人工半抗原、人工抗原及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1498428A1 (en) * | 2003-07-18 | 2005-01-19 | Roche Diagnostics GmbH | Antibodies for detecting ecstasy-class analytes |
CN103360488A (zh) * | 2013-07-05 | 2013-10-23 | 杭州博林生物技术有限公司 | 一种茶碱人工抗原的制备方法 |
CN105367647A (zh) * | 2014-08-21 | 2016-03-02 | 艾博生物医药(杭州)有限公司 | 一种甲基苯丙胺人工抗原的制备方法 |
-
2015
- 2015-11-16 CN CN201510785142.8A patent/CN105315363B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1498428A1 (en) * | 2003-07-18 | 2005-01-19 | Roche Diagnostics GmbH | Antibodies for detecting ecstasy-class analytes |
CN103360488A (zh) * | 2013-07-05 | 2013-10-23 | 杭州博林生物技术有限公司 | 一种茶碱人工抗原的制备方法 |
CN105367647A (zh) * | 2014-08-21 | 2016-03-02 | 艾博生物医药(杭州)有限公司 | 一种甲基苯丙胺人工抗原的制备方法 |
Non-Patent Citations (5)
Title |
---|
卢新生,张志国,贾鑫编著: "《现代有机合成反应技术与应用研究》", 31 October 2014 * |
宋娟: "半抗原的设计、修饰及人工抗原的制备", 《分析化学评述与进展》 * |
晁博: "小分子药物人工抗原的合成与鉴定研究进展", 《药物分析杂志》 * |
洪孝庄: "《蛋白质连接技术》", 30 June 1993 * |
黄培强: "《有机合成》", 30 June 2004 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113087638A (zh) * | 2021-03-11 | 2021-07-09 | 杭州同舟生物技术有限公司 | 一种普瑞巴林人工半抗原、人工抗原及其制备方法和应用 |
WO2022188302A1 (zh) * | 2021-03-11 | 2022-09-15 | 杭州同舟生物技术有限公司 | 一种普瑞巴林人工半抗原、人工抗原及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105315363B (zh) | 2018-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ercegovich et al. | Development of a radioimmunoassay for parathion | |
WO2004038378A2 (en) | Phthalocyanine dyes | |
CN104402753B (zh) | 一种金刚烷胺人工半抗原、人工抗原及其制备方法和应用 | |
CN103360488B (zh) | 一种茶碱人工抗原的制备方法 | |
CN105367647A (zh) | 一种甲基苯丙胺人工抗原的制备方法 | |
CN105315363A (zh) | 一种普瑞巴林人工抗原的制备方法 | |
CN104744294B (zh) | 邻苯二甲酸二(α‑乙基己)酯半抗原、人工抗原及其抗体制备方法及应用 | |
CN103364546B (zh) | 一种检测呋喃唑酮代谢物的试剂盒及方法 | |
CN102627696B (zh) | 一种苯环利定人工抗原的制备方法 | |
CN103360487B (zh) | 一种丙氧酚人工抗原的制备方法 | |
CN114522244B (zh) | 视黄酸修饰的lytac分子及其制备方法和应用 | |
US7498421B2 (en) | Degradation fragments | |
JPS6236040B2 (zh) | ||
CN110357886A (zh) | 甲氨蝶呤半抗原和完全抗原及其制备方法和应用 | |
Frank et al. | Diazoacetyl choline bromide | |
CN111499637B (zh) | 一种育亨宾半抗原yha、人工抗原和其抗体及其制备和应用 | |
CN104558153B (zh) | 一种咖啡因人工抗原的制备方法 | |
CN102861326A (zh) | 流脑多糖-蛋白质缀合疫苗及制备方法 | |
CN105273075B (zh) | 一种托品酰胺人工抗原的制备方法 | |
PT92187B (pt) | Processo para a preparacao de neoglicoproteinas e de agentes de diagnostico que as contem | |
CN103782167B (zh) | 吉西他滨免疫测定 | |
Raviv et al. | Detection of nearest neighbors to specific fluorescently tagged ligands in rod outer segment and lymphocyte plasma membranes by photosensitization of 5-iodonaphthyl-1-azide | |
DE69836279T2 (de) | Neue Verbindung, 2-Amino-3-[2-(α-Mannopyranosyl)indol-3-YL] Propionsäure, Verfahren zur Herstellung und Methoden zur in Vivo Untersuchung mit der neuen Verbindung | |
Yamashita et al. | Intestinal absorption and urinary excretion of antitumor peptidomannan KS-2 after oral administration in rats | |
CN102617730A (zh) | 一种美沙酮人工抗原的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: 310018 550 Yinhai street, Hangzhou economic and Technological Development Zone, Zhejiang Applicant after: Hangzhou Aotai biotechnology Limited by Share Ltd Address before: 310018 550 Yinhai street, Hangzhou economic and Technological Development Zone, Zhejiang Applicant before: Hangzhou Ao Tai Bioisystech Co., Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 310018 Building 5, building 4, building 3, No. 550, Yinhai street, Baiyang street, Hangzhou Economic and Technological Development Zone, Jianggan District, Hangzhou City, Zhejiang Province Patentee after: Hangzhou Aotai biotechnology Limited by Share Ltd Address before: 310018 No. 550, Yinhai street, Hangzhou economic and Technological Development Zone, Zhejiang Patentee before: Hangzhou Aotai biotechnology Limited by Share Ltd |